Cargando…

Extracellular Vesicles and Chemotherapy Resistance in the AML Microenvironment

Extracellular vesicle (EV) trafficking provides for a constitutive mode of cell-cell communication within tissues and between organ systems. Different EV subtypes have been identified that transfer regulatory molecules between cells, influencing gene expression, and altering cellular phenotypes. Evi...

Descripción completa

Detalles Bibliográficos
Autores principales: Nehrbas, Jill, Butler, John T., Chen, Ding-Wen, Kurre, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7033644/
https://www.ncbi.nlm.nih.gov/pubmed/32117744
http://dx.doi.org/10.3389/fonc.2020.00090
_version_ 1783499713962573824
author Nehrbas, Jill
Butler, John T.
Chen, Ding-Wen
Kurre, Peter
author_facet Nehrbas, Jill
Butler, John T.
Chen, Ding-Wen
Kurre, Peter
author_sort Nehrbas, Jill
collection PubMed
description Extracellular vesicle (EV) trafficking provides for a constitutive mode of cell-cell communication within tissues and between organ systems. Different EV subtypes have been identified that transfer regulatory molecules between cells, influencing gene expression, and altering cellular phenotypes. Evidence from a range of studies suggests that EV trafficking enhances cell survival and resistance to chemotherapy in solid tumors. In acute myeloid leukemia (AML), EVs contribute to the dynamic crosstalk between AML cells, hematopoietic elements and stromal cells and promote adaptation of compartmental bone marrow (BM) function through transport of protein, RNA, and DNA. Careful analysis of leukemia cell EV content and phenotypic outcomes provide evidence that vesicles are implicated in transferring several known key mediators of chemoresistance, including miR-155, IL-8, and BMP-2. Here, we review the current understanding of how EVs exert their influence in the AML niche, and identify research opportunities to improve outcomes for relapsed or refractory AML patients.
format Online
Article
Text
id pubmed-7033644
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-70336442020-02-28 Extracellular Vesicles and Chemotherapy Resistance in the AML Microenvironment Nehrbas, Jill Butler, John T. Chen, Ding-Wen Kurre, Peter Front Oncol Oncology Extracellular vesicle (EV) trafficking provides for a constitutive mode of cell-cell communication within tissues and between organ systems. Different EV subtypes have been identified that transfer regulatory molecules between cells, influencing gene expression, and altering cellular phenotypes. Evidence from a range of studies suggests that EV trafficking enhances cell survival and resistance to chemotherapy in solid tumors. In acute myeloid leukemia (AML), EVs contribute to the dynamic crosstalk between AML cells, hematopoietic elements and stromal cells and promote adaptation of compartmental bone marrow (BM) function through transport of protein, RNA, and DNA. Careful analysis of leukemia cell EV content and phenotypic outcomes provide evidence that vesicles are implicated in transferring several known key mediators of chemoresistance, including miR-155, IL-8, and BMP-2. Here, we review the current understanding of how EVs exert their influence in the AML niche, and identify research opportunities to improve outcomes for relapsed or refractory AML patients. Frontiers Media S.A. 2020-02-14 /pmc/articles/PMC7033644/ /pubmed/32117744 http://dx.doi.org/10.3389/fonc.2020.00090 Text en Copyright © 2020 Nehrbas, Butler, Chen and Kurre. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Nehrbas, Jill
Butler, John T.
Chen, Ding-Wen
Kurre, Peter
Extracellular Vesicles and Chemotherapy Resistance in the AML Microenvironment
title Extracellular Vesicles and Chemotherapy Resistance in the AML Microenvironment
title_full Extracellular Vesicles and Chemotherapy Resistance in the AML Microenvironment
title_fullStr Extracellular Vesicles and Chemotherapy Resistance in the AML Microenvironment
title_full_unstemmed Extracellular Vesicles and Chemotherapy Resistance in the AML Microenvironment
title_short Extracellular Vesicles and Chemotherapy Resistance in the AML Microenvironment
title_sort extracellular vesicles and chemotherapy resistance in the aml microenvironment
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7033644/
https://www.ncbi.nlm.nih.gov/pubmed/32117744
http://dx.doi.org/10.3389/fonc.2020.00090
work_keys_str_mv AT nehrbasjill extracellularvesiclesandchemotherapyresistanceintheamlmicroenvironment
AT butlerjohnt extracellularvesiclesandchemotherapyresistanceintheamlmicroenvironment
AT chendingwen extracellularvesiclesandchemotherapyresistanceintheamlmicroenvironment
AT kurrepeter extracellularvesiclesandchemotherapyresistanceintheamlmicroenvironment